Subjects with hemoglobin SC or SB+ thalassemia 
Subjects on chronic transfusion program 
Subjects who have received RBC transfusions cannot have >15% adult hemoglobin 
Known positive status for HIV, active hepatitis B or hepatitis C 
Pregnant or breast feeding women 
Individuals with a history of malignancy are ineligible except for the following circumstances. Individuals with a history of malignancy are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Individuals with the following cancer are eligible if diagnosed and adequately treated within the past 5 years: cervical or breast cancer in situ, and basal cell or squamous cell carcinoma of the skin 
Subjects with a history of thrombosis or other reason (other than sickle cell disease) for enhanced thrombotic risk 
Subjects with unresolved infections 
Severe or uncontrolled medical conditions that could compromise study participation 
Subjects on fetal hemoglobin inducing agents 
Subjects on any other experimental treatment within 90 days of the first dose of study drug or who have not recovered from the side effects of such therapy 
Known allergic reaction to a histone deacetylase inhibitor 
Subjects who have received valproic acid for treatment of epilepsy within 30 days of enrollment 
Subjects who have received any HDAC inhibitors other than valproic acid       
    

NCT01000155_exc_T1
Condition
hemoglobin SC
NCT01000155_exc_T2
Condition
SB+ thalassemia
NCT01000155_exc_T3
Procedure
transfusion program
NCT01000155_exc_T4
Qualifier
chronic
NCT01000155_exc_T5
Multiplier
chronic
NCT01000155_exc_T6
Procedure
RBC transfusions
NCT01000155_exc_T7
Negation
cannot have
NCT01000155_exc_T8
Value
>15% adult hemoglobin
NCT01000155_exc_T9
Condition
HIV
NCT01000155_exc_T10
Condition
hepatitis B
NCT01000155_exc_T11
Condition
hepatitis C
NCT01000155_exc_T12
Temporal
active
NCT01000155_exc_T13
Condition
Pregnant
NCT01000155_exc_T14
Observation
breast feeding
NCT01000155_exc_T15
Person
women
NCT01000155_exc_T16
Condition
malignancy
NCT01000155_exc_T17
Observation
history
NCT01000155_exc_T18
Condition
disease-free
NCT01000155_exc_T19
Temporal
for at least 5 years
NCT01000155_exc_T20
Mood
low risk
NCT01000155_exc_T21
Condition
recurrence of that malignancy
NCT01000155_exc_T22
Condition
that malignancy
NCT01000155_exc_T24
Condition
breast cancer in situ
NCT01000155_exc_T25
Condition
cervical cancer in situ
NCT01000155_exc_T26
Temporal
within the past 5 years
NCT01000155_exc_T27
Condition
squamous cell carcinoma of the skin
NCT01000155_exc_T28
Condition
basal cell carcinoma of the skin
NCT01000155_exc_T30
Negation
are eligible
NCT01000155_exc_T31
Mood
diagnosed
NCT01000155_exc_T32
Mood
adequately treated
NCT01000155_exc_T33
Procedure
treated
NCT01000155_exc_T34
Qualifier
adequately
NCT01000155_exc_T35
Condition
thrombosis
NCT01000155_exc_T36
Condition
sickle cell disease
NCT01000155_exc_T37
Condition
thrombotic risk
NCT01000155_exc_T38
Mood
enhanced risk
NCT01000155_exc_T39
Observation
history
NCT01000155_exc_T40
Negation
other than
NCT01000155_exc_T41
Condition
thrombotic
NCT01000155_exc_T42
Condition
infections
NCT01000155_exc_T43
Qualifier
unresolved
NCT01000155_exc_T44
Condition
medical conditions
NCT01000155_exc_T45
Qualifier
compromise study participation
NCT01000155_exc_T47
Drug
fetal hemoglobin inducing agents
NCT01000155_exc_T48
Qualifier
fetal
NCT01000155_exc_T51
Condition
allergic reaction
NCT01000155_exc_T52
Drug
histone deacetylase inhibitor
NCT01000155_exc_T53
Drug
valproic acid
NCT01000155_exc_T54
Procedure
treatment
NCT01000155_exc_T55
Condition
epilepsy
NCT01000155_exc_T56
Temporal
within 30 days of enrollment
NCT01000155_exc_T57
Reference_point
enrollment
NCT01000155_exc_T58
Drug
HDAC inhibitors
NCT01000155_exc_T59
Negation
other than
NCT01000155_exc_T60
Drug
valproic acid